Emerging Nano-Formulations and Nanomedicines Applications for Ocular Drug Delivery

Dawin Khiev¹, Zeinab A Mohamed¹, Riddhi Vichare¹, Ryan Paulson², Sofia Bhatia², Subhra Mohapatra^{3

4}, Glenn P Lobo⁵, Mallika Valapala⁶, Nagaraj Kerur⁷, Christopher L Passaglia⁸, Shyam S Mohapatra^{1

4

9}, Manas R Biswal^{1

2

9

10}

Affiliations

¹ MSPN Graduate Programs, Taneja College of Pharmacy, University of South Florida, Tampa, FL 33612, USA.
² Department of Pharmaceutical Sciences, Taneja College of Pharmacy, University of South Florida, Tampa, FL 33612, USA.
³ Department of Molecular Medicine, Morsani College of Medicine, University of South Florida, Tampa, FL 33612, USA.
⁴ James A. Haley Veterans' Hospital, Tampa, FL 33612, USA.
⁵ Department of Medicine, Medical University of South Carolina, Charleston, SC 29425, USA.
⁶ School of Optometry, Indiana University, Bloomington, IN 47401, USA.
⁷ Department of Ophthalmology, University of Virginia School of Medicine, Charlottesville, VA 22908, USA.
⁸ Department of Medical Engineering, College of Engineering, Tampa, FL 33620, USA.
⁹ Department of Internal Medicine, Morsani College of Medicine, University of South Florida, Tampa, FL, 33612, USA.
¹⁰ Department of Ophthalmology, Morsani College of Medicine, University of South Florida, Tampa, FL 33612, USA.

PMID: 33445545
PMCID: PMC7828028
DOI: 10.3390/nano11010173

Review

Emerging Nano-Formulations and Nanomedicines Applications for Ocular Drug Delivery

Dawin Khiev et al. Nanomaterials (Basel). 2021.

. 2021 Jan 12;11(1):173.

doi: 10.3390/nano11010173.

Authors

Affiliations

¹ MSPN Graduate Programs, Taneja College of Pharmacy, University of South Florida, Tampa, FL 33612, USA.
² Department of Pharmaceutical Sciences, Taneja College of Pharmacy, University of South Florida, Tampa, FL 33612, USA.
³ Department of Molecular Medicine, Morsani College of Medicine, University of South Florida, Tampa, FL 33612, USA.
⁴ James A. Haley Veterans' Hospital, Tampa, FL 33612, USA.
⁵ Department of Medicine, Medical University of South Carolina, Charleston, SC 29425, USA.
⁶ School of Optometry, Indiana University, Bloomington, IN 47401, USA.
⁷ Department of Ophthalmology, University of Virginia School of Medicine, Charlottesville, VA 22908, USA.
⁸ Department of Medical Engineering, College of Engineering, Tampa, FL 33620, USA.
⁹ Department of Internal Medicine, Morsani College of Medicine, University of South Florida, Tampa, FL, 33612, USA.
¹⁰ Department of Ophthalmology, Morsani College of Medicine, University of South Florida, Tampa, FL 33612, USA.

PMID: 33445545
PMCID: PMC7828028
DOI: 10.3390/nano11010173

Abstract

Ocular diseases can deteriorate vision to the point of blindness and thus can have a major impact on the daily life of an individual. Conventional therapies are unable to provide absolute therapy for all ocular diseases due to the several limitations during drug delivery across the blood-retinal barrier, making it a major clinical challenge. With recent developments, the vast number of publications undergird the need for nanotechnology-based drug delivery systems in treating ocular diseases. The tool of nanotechnology provides several essential advantages, including sustained drug release and specific tissue targeting. Additionally, comprehensive in vitro and in vivo studies have suggested a better uptake of nanoparticles across ocular barriers. Nanoparticles can overcome the blood-retinal barrier and consequently increase ocular penetration and improve the bioavailability of the drug. In this review, we aim to summarize the development of organic and inorganic nanoparticles for ophthalmic applications. We highlight the potential nanoformulations in clinical trials as well as the products that have become a commercial reality.

Keywords: clinical trials; ophthalmic applications; organic and inorganic nanoparticles.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

**Figure 1**
Schematic drawings for potential organic and inorganic nanoparticles for ophthalmic drug delivery.

See this image and copyright information in PMC

References

1. Bourne R.R.A., Flaxman S.R., Braithwaite T., Cicinelli M.V., Das A., Jonas J.B., Keeffe J., Kempen J.H., Leasher J., Limburg H., et al. Vision Loss Expert Group. Magnitude, temporal trends, and projections of the global prevalence of blindness and distance and near vision impairment: A systematic review and meta-analysis. Lancet Glob. Health. 2017;5:e888–e897. doi: 10.1016/S2214-109X(17)30293-0. - DOI - PubMed
1. Kim Y.C., Chiang B., Wu X., Prausnitz M.R. Ocular delivery of macromolecules. J. Control. Release. 2014;190:172–181. doi: 10.1016/j.jconrel.2014.06.043. - DOI - PMC - PubMed
1. Agrahari V., Mandal A., Agrahari V., Trinh H.M., Joseph M., Ray A., Hadji H., Mitra R., Pal D., Mitra A.K. A comprehensive insight on ocular pharmacokinetics. Drug Deliv. Transl. Res. 2016;6:735–754. doi: 10.1007/s13346-016-0339-2. - DOI - PMC - PubMed
1. Urtti A. Challenges and obstacles of ocular pharmacokinetics and drug delivery. Adv. Drug Deliv. Rev. 2006;58:1131–1135. doi: 10.1016/j.addr.2006.07.027. - DOI - PubMed
1. Weng Y., Liu J., Jin S., Guo W., Liang X., Hu Z. Nanotechnology-based strategies for treatment of ocular disease. Acta Pharm. Sin. 2017;7:281–291. doi: 10.1016/j.apsb.2016.09.001. - DOI - PMC - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Emerging Nano-Formulations and Nanomedicines Applications for Ocular Drug Delivery

Affiliations

Emerging Nano-Formulations and Nanomedicines Applications for Ocular Drug Delivery

Authors

Affiliations

Abstract

Conflict of interest statement

Figures

References

Publication types

Grants and funding

LinkOut - more resources

Full Text Sources

Other Literature Sources